Achieve Life Sciences Teams With Omnicon on Nicotine Dependence Treatment

Dow Jones

Jun 27

By Natalie Weger

Achieve Life Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S.

The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment.

Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday.

The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering.

The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes.

Write to Natalie Weger at natalie.weger@wsj.com

(END) Dow Jones Newswires

June 26, 2025 16:56 ET (20:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2546875118"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546875118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546875118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-27 04:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546875118","market":"other","top_or_hot":-1,"title":"Achieve Life Sciences Teams With Omnicon on Nicotine Dependence Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Natalie Weger \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S. \n</p>\n<p>\n  The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment. \n</p>\n<p>\n  Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday. \n</p>\n<p>\n  The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering. \n</p>\n<p>\n  The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Natalie Weger at natalie.weger@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 26, 2025 16:56 ET (20:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Achieve Life Sciences Teams With Omnicon on Nicotine Dependence Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAchieve Life Sciences Teams With Omnicon on Nicotine Dependence Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-27 04:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Natalie Weger \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ACHV\">Achieve Life</a> Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S. \n</p>\n<p>\n  The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment. \n</p>\n<p>\n  Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday. \n</p>\n<p>\n  The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering. \n</p>\n<p>\n  The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Natalie Weger at natalie.weger@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 26, 2025 16:56 ET (20:56 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2546875118","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546875118","pubTimestamp":1750971360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Achieve Life Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S.The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment.Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday.The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering.The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4009":"广告","LU0742537680.HKD":"FIDELITY GLOBAL DIVIDEND \"A \" (HKD) INC","LU1599440770.SGD":"FIDELITY GLOBAL DIVIDEND \"A\" (SGDHDG) INC","ACHV":"Achieve Life Sciences, Inc.","LU0772969993.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) ACC","BK4139":"生物科技","LU0731783048.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) INC MONTHLY (G)","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1509826696.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USD) INC B","LU1481011671.HKD":"FIDELITY GLOBAL DIVIDEND \"A\" (HKDHDG) INC","LU0731783394.SGD":"Fidelity Global Dividend A-MINCOME(G)-SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","OMC":"宏盟集团","LU1481011911.USD":"FIDELITY GLOBAL DIVIDEND \"A\" (USDHDG) INC"},"translate_title":"与Omnicon合作实现生命科学团队的尼古丁依赖治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACHV":0.9,"OMC":0.9},"content_text":"By Natalie Weger \n\n\n \n\n\nAchieve Life Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S. \n\n\n  The pharmaceutical company on Thursday said the collaboration would create a data-driven launch of its treatment. \n\n\n  Achieve submitted its new drug application for cytisinicline, a treatment of nicotine dependence, for approval from the Food and Drug Administration on Wednesday. \n\n\n  The Vancouver, British Columbia, company on Thursday also made a proposed underwritten public offering of its common stock. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of common stock shares or accompanying common warrants. Achieve didn't detail the size or terms of the offering. \n\n\n  The company plans to use the proceeds to fund its cytisinicline advancement through FDA marketing and for other corporate purposes. \n\n\n \n\n\n  Write to Natalie Weger at natalie.weger@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2025 16:56 ET (20:56 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}